Benralizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD125 |
| Clinical data | |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
1044511-01-4  |
| ChemSpider | none |
| UNII |
71492GE1FX  |
| KEGG |
D09874 |
| Chemical and physical data | |
| Formula | C6492H10060N1724O2028S42 |
| Molar mass | 146.0 kg/mol |
| (what is this?) (verify) | |
Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]
Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3]
References
- ↑ Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
- ↑ Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal. 13 (9): 601–604. PMID 20799138.
- ↑ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.